An original combination of lignin and lactulose in the comprehensive therapy of patients with atopic dermatitis and urticaria: results of a multicenter non-interventional study

Introduction. Concomitant gastrointestinal diseases can be a trigger/precipitating factor in the development of atopic dermatitis (AD) and urticaria in children and adults, as well as exacerbate existing systemic inflammation and disrupt the immune balance. The occurrence of these diseases is also associated with disruption of the intestinal microbiota. Objective. To evaluate the effectiveness and safety of a drug containing an original combination of lignin and lactulose in patients with AD and urticaria. Material and methods. The observational program included patients diagnosed with AD with and without signs of food sensitization; urticaria. All patients received a drug containing lignin and lactulose as part of comprehensive therapy according to the regimen of 2—3 tablets 3 times a day for 3 weeks orally 1 hour before meals and taking other medications. Total serum IgE level, dermatological indices (SCORAD, UAS7) and dynamics of concomitant gastrointestinal symptoms were assessed before and after treatment. Results. Among 4000 patients, 2949 were diagnosed with AD, with or without signs of food sensitization; 1051 had urticaria and 581 — concomitant gastrointestinal diseases. With comprehensive therapy, all patients showed a significant reduction in skin manifestations: a reliable (p<0.0001) decrease in the SCORAD index in AD by an average of 58%, the UAS7 index in 67% of patients with urticaria, characterized by a reduction in the number, size of rashes, itching intensity; in 26% of patients, a statistically significant (p<0.0001) decrease in the IgE level (<100 IU/mL) was recorded. The drug was well tolerated, and side effects were reported in 0.2% of participants and did not require withdrawal. Conclusion. Inclusion of the original combination (lignin + lactulose) in comprehensive therapy results in a reduction in skin symptomatology and functional dyspepsia symptoms by the end of the third week in 91—97% of patients with a low risk of adverse events, which allows to recommend its application in patients with AD and urticaria of any severity.